Break Up Facebook? What Would That Even Look Like?

The headline on Facebook co-founder Chris Hughes’ New York Times op-ed article made his position clear. 'It’s Time To Break Up Facebook.' But break up Facebook? How?

May 16, 2019
Warren Buffett an ‘Idiot’?

Famed investor and Berkshire Hathaway CEO Warren Buffett says he wishes he had bought shares early in some of the giants of tech, the so-called FAANG companies whose stocks have consistently outperformed the S&P. Here's why he missed the boat.

May 09, 2019
What Samsung’s Folding Phone Says About Markets

It should have been a banner week for Samsung Electronics, but wasn’t. Instead, it was a master class in 'efficient markets.'

Apr 29, 2019
Five Reasons To Steer Clear of 2019’s Mega IPOs

In what’s poised to be a big year for big-name IPOs, Kass lists five reasons to ease up on the gas pedal and proceed with caution.

Apr 03, 2019
Why the Swiss Want a 1,000-Franc Note

Switzerland’s newest banknote begins circulating this week, and it’s an attention-grabber. It’s not because the new bills are loaded with futuristic security features, however. It’s because they are controversially large.

Mar 13, 2019
Why Do a Corporate Spinoff?

Why would a company with a portfolio of brands seek to do a corporate spinoff? And what does the move mean for shareholders?

Mar 13, 2019
How Do Banks Finance the Unproven Startup?

Banks are the largest source of external financing for startups. Yet banks lack the expertise to monitor startups the way venture capital firms and angel investors do.

Mar 08, 2019
Do Public Firms Get a Bad Rap?

Pressure to deliver quarterly returns can drive managerial myopia. Recent studies link the short-termism to Wall Street culture and dynamics. But a deeper analysis tells a different story.

Mar 04, 2019
Stock Buybacks Are Not the Enemy

Stock buybacks have found themselves in various crosshairs of late, and it’s got Maryland Smith’s David Kass shaking his head. Buybacks, he says, are not the problem.

Feb 18, 2019
Echoes of the Financial Crisis, in Drug Manufacturing

The crisis over tainted heart drugs made in China and sold in the U.S. had an oddly familiar ring to it for Maryland Smith’s Clifford Rossi. But it wasn’t a previous medical drug crisis that crept to mind for him.

Feb 04, 2019